Navigation Links
New target discovered to treat epileptic seizures following brain trauma or stroke
Date:12/5/2008

New therapies for some forms of epilepsy may soon be possible, thanks to a discovery made by a team of University of British Columbia and Vancouver Coastal Health Research Institute neuroscience researchers.

The researchers found that hemichannels - the same channels the researchers previously found to that cause cell death following a stroke - may also cause epileptic seizures that occur following head trauma or a stroke.

The findings, published tomorrow in Science, will allow researchers to focus on new treatments that block these channels. A hemichannel is a channel that can form in nerve cells which allows chemical ions to pass through.

"The glutamate receptor that is linked to cell death following a stroke also triggers opening of hemichannels," says UBC Psychiatry Prof. Brian MacVicar, who is a member of the Brain Research Centre at UBC and VCH Research Institute. "Therefore both stroke itself or the glutamate released by a stroke can open hemichannels and cause cell death or epileptic seizures."

The researchers tested the effect of glutamate at levels less than those reached during stroke and found that more moderate activation of glutamate receptors opens hemichannels and causes seizure but does not produce cell death associated with stroke.

Glutamate is one of the brain's most abundant chemical messengers. Gap junctions are connections that allow molecules and ions, to flow between cells. Junctions are composed of two hemichannels that bridge intercellular space.

When epileptic seizures occur, hemichannels unexpectedly open near the synapses, which disrupt the normal electrical activity of the brain leading to seizures.

"We found that blocking hemichannels reduced the epilepsy-like discharges," says Roger Thompson, a former UBC Psychiatry post-doctoral Fellow who is now an Assistant Professor of Cell Biology, Anatomy and Clinical Neurosciences at the University of Calgary.

"With these results we are confident that the discovery of safe blockers of hemichannels will provide a new therapy in the treatment to reduce cell loss and seizures that are caused by stroke," says MacVicar, who also holds the Canada Research Chair in Neuroscience at UBC.

"The next step will be to develop a compound to block brain cell hemichannels from opening," says MacVicar. "Therapies for epilepsy patients who have suffered a stroke or head trauma may be available within five to 10 years."

According to the BC Epilepsy Society it is estimated that one out of 12 people will have a seizure in their lifetime, and close to one in 100 Canadians have epilepsy. An epileptic seizure is an abnormal burst of electrical activity within the brain.


'/>"/>

Contact: Catherine Loiacono
catherine.loiacono@ubc.ca
604-822-2644
University of British Columbia
Source:Eurekalert

Related medicine news :

1. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
2. NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals
3. WHO tool helps target bone treatment
4. Broccoli compound targets key enzyme in late-stage cancer
5. New breast imaging technology targets hard-to-detect cancers
6. IDO2 an active enzyme to target in pancreatic cancer
7. Experts: Targeted agricultural investments will yield high results, slash poverty in Africa
8. Combining targeted therapy drugs may treat previously resistant tumors
9. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
10. UCSD researchers identify potential new drug target for chronic leukemia
11. TargetScan Evaluation is Shown to Deliver Potentially Higher Cancer Detection Rate and More Accurate Assessment of Grade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited ... compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and ... pleasure to welcome back Dr. Kim to the CDG team” said President and Managing ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based ... US market. , Over the past 20 years SFI has been recognized as the ... launched six new clients into the US market. The new clients include: Panacea ...
(Date:1/19/2017)... ... ... Infinity® Massage Chairs announced today that Dan Grover has joined the organization to ... with a total of 15 years experience in consumer goods and an entrepreneurial mindset, ... Direct Sales at Traeger® Wood Pellet Grills. , Grover has elevated each brand ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the American Osteopathic College of Proctology) announced today the opening of 3 ... California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... A recent ... opened a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Jym Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ... mitochondrial dysfunction, today announced new additions to its senior ... Chief Medical Officer, and Daniel Geffken as ... Jim Carr , Pharm.D. has been promoted to ... pleased to welcome Doug and Daniel to our management ...
(Date:1/19/2017)... Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... analysis instruments and consumables for the medical and veterinary ... its financial results for the third quarter fiscal year ... at 4:15 p.m. ET on Thursday, January 26, 2017.  ... quarter fiscal year 2017 after the market closes on ...
(Date:1/19/2017)... Massachusetts , January 19, 2017 ... ) announced that the U.S. Food and Drug Administration ... of a New Drug Application (NDA) for SHP465, a ... evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder ... on or around June 20, 2017, the designated Prescription ...
Breaking Medicine Technology: